Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
28
SGMT Quote, Financials, Valuation and Earnings
Last price:
$6.07
Seasonality move
:
10.23%
Day range:
$5.96 - $6.12
52-week range:
$1.73 - $11.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.64x
Volume:
134.6K
Avg. volume:
597.4K
1-year change:
22.67%
Market cap:
$195.1M
Revenue:
--
EPS (TTM):
-$1.79
Analysts' Opinion
-
Consensus RatingSagimet Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $28.14, Sagimet Biosciences, Inc. has an estimated upside of 364.4% from its current price of $6.06.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing -312.54% downside risk from its current price of $6.06.
Fair Value
-
According to the consensus of 7 analysts, Sagimet Biosciences, Inc. has 364.4% upside to fair value with a price target of $28.14 per share.
SGMT vs. S&P 500
-
Over the past 5 trading days, Sagimet Biosciences, Inc. has underperformed the S&P 500 by -4.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sagimet Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sagimet Biosciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Sagimet Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Sagimet Biosciences, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sagimet Biosciences, Inc. reported earnings per share of -$0.40.
Enterprise value:
78.5M
EV / Invested capital:
0.66x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.09x
EV / Free cash flow:
-1.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-38.6%
Net Income Margin (TTM):
--
Return On Equity:
-40.34%
Return On Invested Capital:
-40.31%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2M | -- | -- | -- | -- | |
| Gross Profit | $1.9M | -- | -- | -- | -- | |
| Operating Income | -$28.5M | -$45.7M | -$64.3M | -$16.9M | -$14.3M | |
| EBITDA | -$28.4M | -$45.7M | -$64.3M | -$16.9M | -$14.3M | |
| Diluted EPS | -$1.26 | -$1.29 | -$1.79 | -$0.45 | -$0.40 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $102.8M | $156.9M | $119.2M | |
| Total Assets | -- | -- | $102.9M | $174.8M | $128.4M | |
| Current Liabilities | -- | -- | $5M | $4.1M | $9.1M | |
| Total Liabilities | -- | -- | $5.1M | $4.1M | $9.1M | |
| Total Equity | -- | -- | $97.9M | $170.7M | $119.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$24.1M | -$38.5M | -$44.8M | -$19.6M | -$10.2M | |
| Cash From Investing | $37.6M | -$91.2M | $48K | $624K | $75K | |
| Cash From Financing | $86.1M | $104.8M | $275K | -- | $274K | |
| Free Cash Flow | -$24.1M | -$38.5M | -$44.8M | -$19.6M | -$10.2M | |
SGMT
Sector
Market Cap
$195.1M
$28M
Price % of 52-Week High
53.11%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-0.12%
-1.54%
1-Year Price Total Return
22.67%
-17.48%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.11
200-day SMA
Sell
Level
$6.35
Bollinger Bands (100)
Sell
Level
6.48 - 8.2
Chaikin Money Flow
Sell
Level
-1.1M
20-day SMA
Sell
Level
$6.33
Relative Strength Index (RSI14)
Sell
Level
40.55
ADX Line
Neutral
Level
8.49
Williams %R
Neutral
Level
-74.6759
50-day SMA
Sell
Level
$7.23
MACD (12, 26)
Buy
Level
1.61
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
710K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (16.9239)
Buy
CA Score
(Annual)
Level (-0.2614)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (16.6021)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Stock Forecast FAQ
In the current month, SGMT has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SGMT average analyst price target in the past 3 months is $28.14.
-
Where Will Sagimet Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sagimet Biosciences, Inc. share price will rise to $28.14 per share over the next 12 months.
-
What Do Analysts Say About Sagimet Biosciences, Inc.?
Analysts are divided on their view about Sagimet Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sagimet Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Sagimet Biosciences, Inc.'s Price Target?
The price target for Sagimet Biosciences, Inc. over the next 1-year time period is forecast to be $28.14 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SGMT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sagimet Biosciences, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SGMT?
You can purchase shares of Sagimet Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sagimet Biosciences, Inc. shares.
-
What Is The Sagimet Biosciences, Inc. Share Price Today?
Sagimet Biosciences, Inc. was last trading at $6.07 per share. This represents the most recent stock quote for Sagimet Biosciences, Inc.. Yesterday, Sagimet Biosciences, Inc. closed at $6.06 per share.
-
How To Buy Sagimet Biosciences, Inc. Stock Online?
In order to purchase Sagimet Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SGMT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SGMT
Sector
P/E ratio
--
23.89x
PEG ratio
-0.09x
-0.01x
P/B ratio
1.64x
1.82x
Price / LTM sales
--
1.60x
Growth Metrics
SGMT
Sector
Revenue growth
--
4.62%
Earnings growth
12.58%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.39
-$0.21
Profitability
SGMT
Sector
Profitability FY 2024
--
$3.5M
Return on invested capital
-40.31%
-31.77%
Return on assets
-38.6%
-27.96%
Return on equity
-40.34%
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
11
Estimated Next Earnings Date
Feb
12
Balance Sheet
SGMT
Sector
Total cash
$116.7M
$26.3M
Short term investments
$75.4M
$25.7M
Total assets
$160.3M
$78M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
